SOME OBSERVATIONS ON THE USE OF CHLORPROPAMIDE IN PRIMARY TOLBUTAMIDE-FAILURE DIABETICS

Article1 April 1960SOME OBSERVATIONS ON THE USE OF CHLORPROPAMIDE IN PRIMARY TOLBUTAMIDE-FAILURE DIABETICSLEO L. MORGENSTERN, M.B., B.S. (Melbourne)LEO L. MORGENSTERN, M.B., B.S. (Melbourne)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-52-4-761 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptChlorpropamide is a new oral sulfonylurea. Like tolbutamide, the other sulfonylurea presently available in the United States, chlorpropamide has no antibacterial activity. It is rapidly absorbed from the gastrointestinal tract of man; within one hour after a single oral dose it attains readily detectable blood levels,1 which reach a peak within two to four hours.2, 3Chlorpropamide blood levels diminish gradually, the drug being excreted slowly in the urine as the active hypoglycemic material. Within 96 hours, in man, 65 to 90% of a single oral dose of chlorpropamide is excreted in the urine.1The half-time of its disappearance from...Bibliography1. JohnsonHennesDriscollWest PCARTKM: Metabolic fate of chlorpropamide in man, Ann. New York Acad. Sc. 74: 459-472, 1959. CrossrefMedlineGoogle Scholar2. DuncanSchlessDemeshkieh GGGLMM: Clinical experiences with chlorpropamide given to hospitalized patients, Ann. New York Acad. Sc. 74: 717-724, 1959. CrossrefMedlineGoogle Scholar3. LeevyTornowGreenbergZinke CMAPM: Observations on the mode of action and clinical effects of chlorpropamide in diabetes mellitus, Ann. New York Acad. Sc. 74: 725-737, 1959. CrossrefMedlineGoogle Scholar4. KnauffFajansRamirezConn RESSEJW: Metabolic studies of chlorpropamide in normal men and in diabetic subjects, Ann. New York Acad. Sc. 74: 603-617, 1959. CrossrefMedlineGoogle Scholar5. Beaser SB: The correlation between oral dosage, blood levels, and clinical and metabolic activity of chlorpropamide in the treatment of diabetes mellitus, Ann. New York Acad. Sc. 74: 701-708, 1959. CrossrefMedlineGoogle Scholar6. LevineDuncan RGG, Editors: Symposium on clinical and experimental effects of sulfonylureas in diabetes mellitus, Metabolism 5: 721-977, 1956. MedlineGoogle Scholar7. Levine R (Consulting Editor): The effects of the sulfonylureas and related compounds in experimental and clinical diabetes, Ann. New York Acad. Sc. 71: 1-292, 1959. Google Scholar8. Goldner M (Consulting Editor): Chlorpropamide and diabetes mellitus, Ann. New York Acad. Sc. 74: 407-1028, 1959. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: White Plains, N. Y.*Received for publication June 8, 1959.This study of the effects of a new oral antidiabetic compound, chlorpropamide (Diabinese, Pfizer P-607) was carried out in the Metabolic Clinic of the White Plains Hospital, White Plains, N. Y., in 1958.†This study was aided by a grant from Charles Pfizer & Co.Requests for reprints should be addressed to Leo L. Morgenstern, M.B., B.S., 205 West Post Road, White Plains, N. Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1960Volume 52, Issue 4Page: 761-772KeywordsAttentionBloodDrugsGastrointestinal tractHospitalsHypoglycemicsInsulinUrine ePublished: 1 December 2008 Issue Published: 1 April 1960 PDF downloadLoading ...